NAC & Mental Health

The psychiatric evidence base for NAC is one of the most surprising in medicine. Over the past 15 years, large teams at Deakin University (Michael Berk), the University of Minnesota (Jon Grant), Stanford (Antonio Hardan), and the Medical University of South Carolina (Kevin Gray, Sudie Back) have generated a steady stream of randomized controlled trials showing that NAC, as an adjunct, produces measurable benefit in obsessive-compulsive disorder, trichotillomania, excoriation disorder, schizophrenia, bipolar depression, major depression, adolescent cannabis use disorder, autism-related irritability, and PTSD with substance use. The effect sizes are small-to-moderate, but for disorders where many trials produce nothing, they stand out.

The core hypothesis: psychiatric disorders involve dysregulated glutamate signaling and oxidative stress in corticostriatal and limbic circuits. NAC addresses both through a single molecular intervention — glutathione replenishment plus glutamate normalization through the cystine-glutamate antiporter. This article walks through each indication.

Table of Contents

1. Brain Mechanisms: Glutamate, Glutathione, Neuroinflammation
2. Obsessive-Compulsive Disorder and Grooming Disorders
3. Major Depressive Disorder
4. Bipolar Disorder
5. Schizophrenia
6. Addiction and Substance Use Disorder
7. Autism Spectrum Disorder
8. PTSD and Trauma
9. Alzheimer's and Cognitive Decline
10. Dosing in Psychiatry
11. Safety
12. References
13. Connections
14. Featured Videos

Brain Mechanisms: Glutamate, Glutathione, Neuroinflammation

The Cystine-Glutamate Antiporter (System xc-)

NAC is deacetylated to cysteine, oxidized to cystine, then imported into astrocytes via system xc- in exchange for glutamate. Extrasynaptic glutamate stimulates inhibitory presynaptic mGluR2/3 receptors that downregulate pathological synaptic glutamate release. This is the mechanism by which NAC normalizes glutamate homeostasis in the nucleus accumbens (addiction), dorsomedial striatum (OCD), and prefrontal cortex (schizophrenia, depression) — work largely done in the Kalivas laboratory at MUSC.

Glutathione and Oxidative Stress

Schizophrenia, bipolar disorder, and major depression all show reduced glutathione in the anterior cingulate cortex on magnetic resonance spectroscopy (Do 2009, Yao and Keshavan 2011). Post-mortem schizophrenia tissue shows ~50% reduction in cortical glutathione. NAC restores the substrate for glutathione synthesis directly.

Neuroinflammation

Elevated peripheral inflammatory markers (IL-6, TNF-alpha, CRP) are replicated findings in depression and bipolar disorder meta-analyses (Dowlati 2010). NAC suppresses NF-kB signaling and attenuates microglial activation. Berk's "redox-glutamate-inflammation triangle" model captures how the three mechanisms reinforce each other.

Obsessive-Compulsive Disorder and Grooming Disorders

OCD is associated with elevated glutamate in the caudate and orbitofrontal cortex on MRS (Rosenberg 2000). NAC is used adjunctively with SSRIs in treatment-resistant OCD.

Key OCD Trials

• Afshar 2012 (J Clin Psychopharmacol): 48 SSRI-refractory OCD adults, 12-week RCT, NAC 2,400 mg/day adjunctive to fluvoxamine. Partial response 52.6% (NAC) vs 15% (placebo); effect primarily on compulsions.
• Paydary 2016 (J Clin Pharm Ther): 44 OCD adults, 10-week NAC 2 g/day adjunctive to fluoxetine. NAC group had roughly 4-point greater Y-BOCS reduction and higher response rate.
• Sarris 2015 (CNS Drugs): 16-week RCT, 44 OCD adults, NAC 3 g/day monotherapy / adjunct. Overall negative on Y-BOCS at 16 weeks; secondary analyses suggested benefit in non-SSRI subgroup.
• Costa 2017 (J Clin Psychiatry): 16-week RCT, 40 SSRI-refractory OCD adults, 3 g/day NAC. Negative primary outcome; anxiety subscale improved.

Trichotillomania (Hair-Pulling)

• Grant 2009 (Arch Gen Psychiatry): 12-week RCT, 50 adults, NAC up to 2,400 mg/day. 56% of NAC patients rated much/very much improved versus 16% placebo. Landmark trial that launched the NAC-grooming-disorder field.
• Bloch 2013 (JAACAP): 12-week pediatric RCT in 39 children/adolescents — negative. NAC did not separate from placebo in pediatric trichotillomania.

Excoriation (Skin-Picking) Disorder

• Grant 2016 (JAMA Psychiatry): 12-week RCT, 66 adults, NAC up to 3,000 mg/day. 47% NAC vs 19% placebo rated much improved on NE-YBOCS.

Nail Biting

Ghanizadeh 2013 small pediatric trial (NAC 800 mg/day): modest reduction at 1 month, not sustained at 2 months.

Major Depressive Disorder

• Berk 2014 (J Clin Psychiatry): 252 MDD participants, 12-week adjunctive NAC 2 g/day with 4-week washout. No significant separation at week 12 on MADRS but significant advantage at week 16 post-washout, suggesting delayed onset. NAC superior on functional measures (SOFAS, LIFE-RIFT).
• Fernandes 2016 (J Clin Psychiatry meta-analysis): Pooled 5 NAC RCTs (n=574). NAC significantly improved depressive symptoms (SMD -0.37, 95% CI -0.62 to -0.13) and functionality.
• Hasebe 2017 (BJPsych Open): participant-level meta-analysis confirmed adjunctive benefit.

Bipolar Disorder

• Berk 2008 (Biol Psychiatry): 8-week RCT in 75 bipolar patients (mostly depressive phase). NAC 2 g/day adjunct reduced MADRS by ~8 points more than placebo. Benefits lost after washout, suggesting state effect.
• Berk 2012 (BMC Medicine): 149-patient maintenance study; modest benefits mostly on functional measures.
• Berk 2019 (BMC Medicine CEASE trial): 16-week RCT of NAC alone, NAC + mitochondrial cocktail, or placebo in 181 bipolar depression patients. Primary MADRS outcome negative.
• Pittas 2021 meta-analysis: small-to-moderate benefit for bipolar depression (SMD ~0.45); no clear effect on mania.

Clinically, NAC is framed as a low-risk adjunct for bipolar depression and overall functioning — not a replacement for lithium, valproate, or atypicals.

Schizophrenia

• Berk 2008 (Biol Psychiatry): 24-week RCT, 140 chronic schizophrenia patients on antipsychotics, NAC 2 g/day. Significantly improved PANSS total, especially negative symptoms and general psychopathology. Improved CGI-Severity and reduced akathisia. Effects emerged around week 8 and were lost after washout.
• Farokhnia 2013 (Clin Neuropharmacol): 8-week RCT, 42 chronic schizophrenia, NAC 2 g/day adjunct to risperidone — greater PANSS negative-symptom improvement.
• Conus 2018 (Schizophr Bull): 6-month RCT in early psychosis, NAC 2,700 mg/day. Improved cognition (processing speed) and reduced positive symptoms in the subgroup with high peripheral oxidative stress.
• Yolland 2020 (Aust NZ J Psychiatry meta-analysis): 7 RCTs pooled; adjunctive NAC significantly improved PANSS total, negative symptoms, and working memory.

Addiction and Substance Use Disorder

Chronic drug use dysregulates nucleus accumbens glutamate — reduced basal extracellular glutamate and blunted mGluR2/3 inhibitory tone. NAC restores homeostasis via system xc-.

Cocaine

• LaRowe 2007 (open-label): NAC 2,400 mg/day reduced cocaine craving and use.
• LaRowe 2013 (Am J Psychiatry): 8-week RCT in 111 cocaine-dependent adults. Primary outcome negative, but in already-abstinent subgroup NAC prolonged time to relapse. Better for relapse prevention than induction.

Cannabis

• Gray 2012 (Am J Psychiatry): 8-week RCT, 116 cannabis-dependent adolescents, NAC 1,200 mg BID plus contingency management. NAC group more than doubled odds of negative urine cannabinoid tests (OR 2.4). Landmark adolescent addiction RCT.
• Gray 2017 (Drug Alcohol Depend): NIDA CTN multisite RCT in 302 adults — negative. NAC did not separate from placebo in adults.

Nicotine

• Schmaal 2011 (Eur Addict Res): 3.5-day NAC 2,400 mg/day reduced cigarettes smoked and reward value.
• Prado 2015: 12-week NAC reduced cigarettes/day.

Other Substances

• Methamphetamine: Mousavi 2015 — NAC 1,200 mg/day reduced craving in detoxification.
• Gambling: Grant 2007 — 59% of pathological gamblers showed craving reduction on open-label NAC, maintained in double-blind discontinuation.
• Alcohol: Squeglia 2018 feasibility data in alcohol use disorder.

Autism Spectrum Disorder

• Hardan 2012 (Biol Psychiatry, Stanford): 12-week double-blind RCT, 33 children with ASD, NAC titrated to 900 mg TID (2,700 mg/day). Significant reduction on Aberrant Behavior Checklist irritability subscale (ABC-I), effect size roughly 1 standard deviation. Stereotypy also improved.
• Ghanizadeh 2013 (BMC Psychiatry): 8-week RCT, 40 ASD children on risperidone, NAC 1,200 mg/day. Significant ABC-Irritability reduction.
• Nikoo 2015 confirmed risperidone + NAC advantage for irritability.
• Wink 2016 (J Child Adolesc Psychopharmacol): Negative RCT for core ASD symptoms — reinforces that NAC's ASD benefit is primarily irritability and self-injury, not core social or communication features.
• Dean 2017 (Transl Psychiatry review): Pooled pediatric ASD data; consistent moderate effect on irritability.

PTSD and Trauma

• Back 2016 (J Clin Psychiatry): 8-week RCT, 35 veterans with comorbid PTSD and substance use disorder, NAC 2,400 mg/day + CBT. NAC significantly reduced PTSD Checklist (PCL) scores and craving. First RCT supporting NAC for PTSD, notable because PTSD-SUD comorbidity is treatment-resistant.
• Back 2020 expanded PTSD-SUD protocols.
• Szuhany 2022 pilot NAC + prolonged exposure — feasibility and signal data supportive; larger trials ongoing.

Alzheimer's and Cognitive Decline

• Adair 2001 (Neurology): 6-month pilot RCT of NAC 50 mg/kg/day in probable Alzheimer's (n=47). No change on primary cognitive outcome; trends on secondary measures.
• Remington 2015 (J Alzheimers Dis): Nutraceutical formulation (NAC + folate + B12 + alpha-tocopherol + SAMe + acetyl-L-carnitine) improved Dementia Rating Scale — but that is not pure NAC.

Animal models of Alzheimer's (APP/PS1 mice) show reduced amyloid and improved memory with NAC, but clinical translation remains incomplete. NAC is not currently a recommended AD therapy.

Dosing in Psychiatry

• Adults: 2,000–2,400 mg/day divided (600 mg QID or 1,200 mg BID); some schizophrenia and OCD trials go to 3,000 mg/day.
• Pediatric: titrated from 900 mg/day to 2,700 mg/day (Hardan ASD protocol); adolescent cannabis trials used 1,200 mg BID.
• Titration: start 600–1,200 mg/day and increase over 1–2 weeks to reduce GI side effects.
• Trial duration: most positive trials run 8–12 weeks; schizophrenia and bipolar maintenance extend to 24 weeks. Effects often emerge around weeks 4–8 and may require 12+ weeks for full response.
• Formulation: effervescent and capsule both used. Absorption is low and variable (~10% oral bioavailability), justifying the high doses.

Safety

• GI upset is the main adverse effect: nausea, vomiting, diarrhea, heartburn. Usually mild and dose-related.
• Unpleasant sulfur taste/smell.
• Headache, rash (uncommon).
• Minimal drug interactions: theoretical nitroglycerin potentiation, mild platelet effects, activated-charcoal binding.
• Pregnancy Category B.
• No tolerance, dependence, or withdrawal.
• Overdose risk extremely low.

Clinically, NAC is best positioned as a low-risk adjunctive intervention added to standard care (SSRIs for OCD, antipsychotics for schizophrenia, mood stabilizers for bipolar, CBT for PTSD) — not a standalone replacement for first-line psychiatric treatment.

References

1. Berk M, Copolov DL, Dean O, et al. NAC as a glutathione precursor for schizophrenia — RCT. Biol Psychiatry 2008;64(5):361–368. PMID 18436195.
2. Berk M, Copolov DL, Dean O, et al. NAC for depressive symptoms in bipolar disorder — RCT. Biol Psychiatry 2008;64(6):468–475. PMID 18534556.
3. Berk M, Dean OM, Cotton SM, et al. Maintenance NAC for bipolar disorder: RCT. BMC Medicine 2012;10:91. PMID 22891797.
4. Berk M, Turner A, Malhi GS, et al. Mitochondrial agents, NAC, and placebo for bipolar depression (CEASE). BMC Medicine 2019;17(1):18. PMID 30678686.
5. Berk M, Dean OM, Cotton SM, et al. Efficacy of adjunctive NAC in MDD: RCT. J Clin Psychiatry 2014;75(6):628–636. PMID 25004186.
6. Fernandes BS, Dean OM, Dodd S, Malhi GS, Berk M. NAC in depressive symptoms and functionality: systematic review / meta-analysis. J Clin Psychiatry 2016;77(4):e457–466. PMID 27137430.
7. Afshar H, Roohafza H, Mohammad-Beigi H, et al. NAC add-on in refractory OCD: RCT. J Clin Psychopharmacol 2012;32(6):797–803. PMID 23131885.
8. Sarris J, Oliver G, Camfield DA, et al. NAC in OCD: 16-week RCT. CNS Drugs 2015;29(9):801–809.
9. Paydary K, Akamaloo A, Ahmadipour A, et al. NAC augmentation in OCD: RCT. J Clin Pharm Ther 2016;41(2):214–219. PMID 26931055.
10. Grant JE, Odlaug BL, Kim SW. NAC in trichotillomania: RCT. Arch Gen Psychiatry 2009;66(7):756–763. PMID 19581567.
11. Grant JE, Chamberlain SR, Redden SA, Leppink EW, Odlaug BL, Kim SW. NAC in excoriation disorder: RCT. JAMA Psychiatry 2016;73(5):490–496. PMID 27007062.
12. Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. NAC in pediatric trichotillomania: RCT. JAACAP 2013;52(3):231–240. PMID 23452680.
13. Gray KM, Carpenter MJ, Baker NL, et al. NAC in cannabis-dependent adolescents: RCT. Am J Psychiatry 2012;169(8):805–812. PMID 22706327.
14. Gray KM, Sonne SC, McClure EA, et al. NAC for cannabis use disorder in adults: RCT. Drug Alcohol Depend 2017;177:249–257. PMID 28623823.
15. LaRowe SD, Kalivas PW, Nicholas JS, et al. NAC in cocaine dependence: RCT. Am J Addict 2013;22(5):443–452. PMID 23952889.
16. Schmaal L, Berk L, Hulstijn KP, et al. NAC in nicotine dependence: RCT. Eur Addict Res 2011;17(4):211–216. PMID 21606648.
17. Back SE, McCauley JL, Korte KJ, et al. NAC in veterans with PTSD and SUD: RCT. J Clin Psychiatry 2016;77(11):e1439–e1446. PMID 27736051.
18. Hardan AY, Fung LK, Libove RA, et al. NAC in children with autism: RCT. Biol Psychiatry 2012;71(11):956–961. PMID 22342106.
19. Ghanizadeh A, Moghimi-Sarani E. NAC added to risperidone in autistic disorders: RCT. BMC Psychiatry 2013;13:196. PMID 23886027.
20. Yolland CO, Hanratty D, Neill E, et al. Meta-analysis of NAC RCTs in schizophrenia. Aust NZ J Psychiatry 2020;54(5):453–466. PMID 31980007.
21. Deepmala, Slattery J, Kumar N, et al. Clinical trials of NAC in psychiatry and neurology: systematic review. Neurosci Biobehav Rev 2015;55:294–321. PMID 25957927.
22. Berk M, Malhi GS, Gray LJ, Dean OM. The promise of NAC in neuropsychiatry. Trends Pharmacol Sci 2013;34(3):167–177. PMID 23369637.
23. Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009;10(8):561–572. PMID 19571793.

Connections

• NAC Overview
• NAC & Glutathione
• Natural Anxiety Relief
• Gut-Brain Axis
• Sleep Hygiene
• Depression
• Anxiety
• OCD
• Bipolar Disorder
• Schizophrenia
• Autism Spectrum Disorder
• Cysteine
• Glycine

↑ Back to Table of Contents

Featured Videos

NAC in Psychiatry — Professor Michael Berk

NAC for OCD and Trichotillomania

Glutamate Homeostasis and Addiction